Tumor resistance to HER2 inhibitors: The drug sedimentation concept;Échappement tumoral aux inhibiteurs de HER2: Théorie de la sédimentation

Bulletin du Cancer

Volumn 99, Issue 6, 2012, Pages 665-672

  Campone, Mario ^a,b   Frenel, Jean Sébastien ^a   André, Fabrice ^c   Bachelot, Thomas ^d   Juin, Philippe ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Team 12   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Lapatinib; Predictive factors; Resistance; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB;

BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER PATIENT; DORMANCY; DRUG EFFICACY; GENE AMPLIFICATION; HUMAN; ONCOGENE; PROTEIN EXPRESSION; REVIEW; SEDIMENTATION; TUMOR CELL; TUMOR RESISTANCE;

EID: 84862902435     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1591     Document Type: Article

References (35)

1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 : 719-26. (Pubitemid 34111379)
2. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26 : 2999-3005.
3. Merlin JL, Barberi-Heyob M, Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Ann Oncol 2002; 13 : 1743-8. (Pubitemid 35439454)
4. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin® in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304 : 604-19. (Pubitemid 40321136)
5. Marches R, Uhr JW. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin®) on HER2-overexpressing tumor cells. Int J Cancer 2004; 112 : 492-501. (Pubitemid 39390616)
6. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6 : 443-6. (Pubitemid 30208162)
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 : 2639-48. (Pubitemid 29415219)
8. Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008; 30 : 1426-47.
9. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19 : 1068-74. (Pubitemid 351796331)
10. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008; 26 : 1066-72.
11. Nagy P, Friedlander E, Tanner M, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65 : 473-82.
12. Palyi-Krekk Z, Barok M, Isola J, Tammi M, Szollosi J, Nagy P. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 2007; 43 : 2423-33. (Pubitemid 47625976)
13. Campone M, Juin P, André F, Bachelot T. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol Hematol 2011; 78 : 195-205.
14. Valabrega G, Montemurro F, Sarotto I, et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005; 24 : 3002-10. (Pubitemid 40675531)
15. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin®). J Natl Cancer Inst 2001; 93 : 1852-7. (Pubitemid 34048651)
16. Shattuck DL, Miller JK, Carraway 3rd. KL, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68 : 1471-7. (Pubitemid 351346855)
17. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6 : 117-27. (Pubitemid 39485684)
18. Perez EA, Dueck AC, Reinholz MM, et al. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl.). (abstr 10504).
19. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68 : 9221-30.
20. Hu X,Wang LP, Zhang QL, et al. An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl.). (abstr 541).
21. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445 : 437-41. (Pubitemid 46160912)
22. Xia W, Bacus S, Hegde P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103 : 7795-800.
23. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 1997; 3 : 2696-702. (Pubitemid 28133129)
24. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 : 747-52.
25. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10 : 425-35.
26. Staaf J, Ringnér M, Vallon-Christersson J, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010; 28 : 1813-20.
27. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997; 8 : 1075-80. (Pubitemid 27521214)
28. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353 : 793-802. (Pubitemid 41215488)
29. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28 : 1124-30.
30. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28 : 1138-44.
31. Baselga J, Cortes J, Fumoleau P, et al. Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with her2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. 2009 (SABCS Annual Meeting).
32. Modi S, Stopeck A, Kinden H. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2- positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial. (SABCS) Annual meeting 2007:6066.
33. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28 : 5110-5.
34. Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio breast cancer symposium; 2007.
35. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366 : 109-19.